A phase II study evaluating the toxicity and efficacy of single-agent temsirolimus in chemotherapy-naïve castration-resistant prostate cancer
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
http://www.nature.com/articles/bjc2013530.pdf
Reference48 articles.
1. Alvarez EA, Brady WE, Walker JL, Rotmensch J, Zhou XC, Kendrick JE, Yamada SD, Schilder JM, Cohn DE, Harrison CR, Moore KN, Aghajanian C (2013) Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 129 (1): 22–27.
2. 1. Armstrong A, Shen T, Halabi S, Kemeny G, Bitting R, Kartcheske P, Embree E, Morris K, Winters C, Jaffe T, Fleming M, George D (2013) A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer. Clin Genitourin Cancer
3. 2. e-pub ahead of print 3 July 2013
4. 10.1016/j.clgc.2013.05.007
5. Behbakht K, Sill MW, Darcy KM, Rubin SC, Mannel RS, Waggoner S, Schilder RJ, Cai KQ, Godwin AK, Alpaugh RK (2011) Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study. Gynecol Oncol 123 (1): 19–26.
Cited by 49 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The role of autophagy in prostate cancer and prostatic diseases: a new therapeutic strategy;Prostate Cancer and Prostatic Diseases;2024-01-31
2. Genomic Discoveries: Precision Medicine and Personalized Approaches in Prostate Cancer Care;Transforming Prostate Cancer Care;2024
3. Crosstalk between Endothelial Cells and Tumor Cells: A New Era in Prostate Cancer Progression;International Journal of Molecular Sciences;2023-11-29
4. The Molecular Biology of Prostate Cancer Stem Cells: From the Past to the Future;International Journal of Molecular Sciences;2023-04-19
5. OncoLoop: A Network-Based Precision Cancer Medicine Framework;Cancer Discovery;2022-11-14
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3